APO RESEARCH · REPORT
Lenalidomide
Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS). For MM it is used after at least one other treatment and generally together with dexamethasone.
Product & engineering
Understand the product.
Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS). For MM it is used after at least one other treatment and generally together with dexamethasone.
Selected research
Industry Research
Lenalidomide Industry Research Report 2026
Market perspective
Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS). For MM it is used after at least one other treatment and generally together with dexamethasone.
In China, Lenalidomide key players include Celgene, SL Pharma.
In terms of product, 25 mg Capsules is the largest segment, with a share over 40%. And in terms of application, the largest application is Multiple myeloma (MM), followed by Myelodysplastic syndromes (MDS).
Read the full market overview
Report Scope
This report quantifies the global Lenalidomide market in terms of revenue (US$ million) and, where applicable, sales volume (K Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lenalidomide Market by Company
Celgene
SL Pharma
Lenalidomide Segment by Type
5 mg Capsules
10 mg Capsules
15 mg Capsules
25 mg Capsules
Lenalidomide Segment by Application
Multiple myeloma (MM)
Myelodysplastic syndromes (MDS)
Lenalidomide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lenalidomide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lenalidomide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lenalidomide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Lenalidomide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Lenalidomide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Lenalidomide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 5 mg Capsules
- 10 mg Capsules
- 15 mg Capsules
- 25 mg Capsules
Applications
- Multiple myeloma (MM)
- Myelodysplastic syndromes (MDS)
Companies covered
- Celgene
- SL Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Lenalidomide Market Size (2021-2032)
- 2.2.2 Global Lenalidomide Sales (2021-2032)
- 2.2.3 Global Lenalidomide Market Average Price (2021-2032)
- 2.3 Lenalidomide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 5 mg Capsules
- 2.3.3 10 mg Capsules
- 2.3.4 15 mg Capsules
- 2.3.5 25 mg Capsules
- 2.4 Lenalidomide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Multiple myeloma (MM)
- 2.4.3 Myelodysplastic syndromes (MDS)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Lenalidomide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Lenalidomide Sales (K Pcs) of Manufacturers (2021-2026)
- 3.3 Global Lenalidomide Revenue of Manufacturers (2021-2026)
- 3.4 Global Lenalidomide Average Price by Manufacturers (2021-2026)
- 3.5 Global Lenalidomide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Lenalidomide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Lenalidomide, Product Type & Application
- 3.8 Global Manufacturers of Lenalidomide, Established Date
- 3.9 Global Lenalidomide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Celgene
- 4.1.1 Celgene Company Information
- 4.1.2 Celgene Business Overview
- 4.1.3 Celgene Lenalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Celgene Lenalidomide Product Portfolio
- 4.1.5 Celgene Recent Developments
- 4.2 SL Pharma
- 4.2.1 SL Pharma Company Information
- 4.2.2 SL Pharma Business Overview
- 4.2.3 SL Pharma Lenalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 SL Pharma Lenalidomide Product Portfolio
- 4.2.5 SL Pharma Recent Developments
5 Global Lenalidomide Market Scenario by Region
- 5.1 Global Lenalidomide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Lenalidomide Sales by Region: 2021-2032
- 5.2.1 Global Lenalidomide Sales by Region: 2021-2026
- 5.2.2 Global Lenalidomide Sales by Region: 2027-2032
- 5.3 Global Lenalidomide Revenue by Region: 2021-2032
- 5.3.1 Global Lenalidomide Revenue by Region: 2021-2026
- 5.3.2 Global Lenalidomide Revenue by Region: 2027-2032
- 5.4 North America Lenalidomide Market Facts & Figures by Country
- 5.4.1 North America Lenalidomide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Lenalidomide Sales by Country (2021-2032)
- 5.4.3 North America Lenalidomide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Lenalidomide Market Facts & Figures by Country
- 5.5.1 Europe Lenalidomide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Lenalidomide Sales by Country (2021-2032)
- 5.5.3 Europe Lenalidomide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Lenalidomide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Lenalidomide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Lenalidomide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Lenalidomide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Lenalidomide Market Facts & Figures by Country
- 5.7.1 South America Lenalidomide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Lenalidomide Sales by Country (2021-2032)
- 5.7.3 South America Lenalidomide Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Lenalidomide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Lenalidomide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Lenalidomide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Lenalidomide Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Lenalidomide Sales by Type (2021-2032)
- 6.1.1 Global Lenalidomide Sales by Type (2021-2032) & (K Pcs)
- 6.1.2 Global Lenalidomide Sales Market Share by Type (2021-2032)
- 6.2 Global Lenalidomide Revenue by Type (2021-2032)
- 6.2.1 Global Lenalidomide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Lenalidomide Revenue Market Share by Type (2021-2032)
- 6.3 Global Lenalidomide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Lenalidomide Sales by Application (2021-2032)
- 7.1.1 Global Lenalidomide Sales by Application (2021-2032) & (K Pcs)
- 7.1.2 Global Lenalidomide Sales Market Share by Application (2021-2032)
- 7.2 Global Lenalidomide Revenue by Application (2021-2032)
- 7.2.1 Global Lenalidomide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Lenalidomide Revenue Market Share by Application (2021-2032)
- 7.3 Global Lenalidomide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Lenalidomide Value Chain Analysis
- 8.1.1 Lenalidomide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Lenalidomide Production Mode & Process
- 8.2 Lenalidomide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Lenalidomide Distributors
- 8.2.3 Lenalidomide Customers
9 Global Lenalidomide Analyzing Market Dynamics
- 9.1 Lenalidomide Industry Trends
- 9.2 Lenalidomide Industry Drivers
- 9.3 Lenalidomide Industry Opportunities and Challenges
- 9.4 Lenalidomide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst